CN105963757A - Autolyzed hemostatic composite material and preparation method thereof - Google Patents
Autolyzed hemostatic composite material and preparation method thereof Download PDFInfo
- Publication number
- CN105963757A CN105963757A CN201610474468.3A CN201610474468A CN105963757A CN 105963757 A CN105963757 A CN 105963757A CN 201610474468 A CN201610474468 A CN 201610474468A CN 105963757 A CN105963757 A CN 105963757A
- Authority
- CN
- China
- Prior art keywords
- parts
- autolyzed
- chitosan
- component
- hemostasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/34—Oils, fats, waxes or natural resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Abstract
The invention relates to an autolyzed hemostatic composite material and a preparation method thereof. The autolyzed hemostatic composite material comprises the following components in parts by weight: 5-15 parts of Yunnan Baiyao, 10-30 parts of chitosan, 2-5 parts of alum, 4-10 parts of cod-liver oil, 2-8 parts of amino acid, 5-10 parts of acetic acid, 1-3 parts of chitosan, 6-12 parts of sorbic acid, 4-12 parts of gelatin, 3-6 parts of collagen protein, 4-10 parts of sodium alginate and 6-10 parts of sago starch. The autolyzed hemostatic composite material can provide a powerful wet recovery environment for wounds, is good in biological compatibility, can be gradually absorbed by a body, can be gradually degraded into monosaccharide to be absorbed by the human body after being in contact with lytic enzymes and the like and does not need to be taken out when being used in the human body, so that the pain of a patient can be reduced, and the secondary damage to the wounds is reduced; the autolyzed hemostatic composite material is high in hemostatic speed, easy to absorb and convenient to use.
Description
Technical field
The invention belongs to hemostatic material in medical use technical field, be specifically related to a kind of autolyzed hemostasis composite and preparation thereof
Method.
Background technology
In daily life injured unavoidable, thus topical hemostatic agent seems extremely important.Such as daily sudden accident
Emergency treatment, hospital to the wound hemostasis of patient being all often required to use, the rescue etc. that particularly war is injured.Existing only
Blood gauze, the hemostatic material such as stanch fibre and tourniquet bandage in use has certain limitation: easily do not allow with wound adhesion
Easily change dressings, the most helpless to infection and suppurative wound.The unnecessary death caused because losing blood for minimizing, various countries' medical circle
Requirement to hemostatic material anthemorrhagic performance is higher, develops haemostatic effect more preferably material imperative.As bleeding-stopping dressing
Or the material of hemorrhage to possess good anthemorrhagic performance, excellent biocompatibility, have no side effect, nonirritant, it is easy to
Machine-shaping etc..Therefore, from existing condition, find in nature excellent biomaterial and processed, just improve
Become a kind of preferably to select.
Along with surgical technic is fast-developing, hemostatic material have also been obtained rapid progress.Such as Linz, AUT city Hafs
The Tachocomd that Lund Nycomed pharmaceuticals develops can absorb Wound hemostatic sealant, Gelfix hemostatic material with
And Surgicel regenerated cellulose hemostatic material etc..Surgical operation and zoopery the most fully demonstrate its haemostatic effect.Meanwhile,
Experiment in vitro also demonstrates the anthemorrhagic performance that it is excellent.Zhao Hongxia etc. utilize collagen protein and chitosan to be prepared for composite membrane, greatly
The cost and the anastalsis that reduce greatly sthptic sponge are good, are also a kind of preferably hemostatic materials.The hemostasis of stone photoproduction invention
Fenbid cuticula aerosol is exactly a kind of liquid hemostatic material, uses the liquefied butane containing propane to make propellant, does with chlohexidine
Disinfectant, dyclonine is cooked surface local anesthetic, and ethyl acetate makees solvent, and ethanol makees cosolvent, additionally adds appropriate two
Carbonoxide, makees film former etc. with poly-methacrylate ethoxy ethyl ester (or polyvinyl acetate).Additionally, the development such as Zhu Yun is novel
Silica hydrogel burn wound aerosol, uses silicone to make film former, and the trimerization tert-butyl alcohol makees cosolvent, separately adds antibacterial analgesic, impelling
Agent etc. are made.After the sprayable aerosol of the processed one-tenth of aqueous hemostatic material easy to use, be worth of widely use.Above-mentioned hemostasis
The hemostatic gauze that material is the most traditional, stanch fibre and tourniquet bandage are easily and wound is viscous, are difficult to change, use inconvenience；And liquid
Body hemostatic material is many containing various organic solvents, dangerous environmental protection.
Summary of the invention
The invention aims to provide a kind of autolyzed hemostasis composite and preparation method thereof.
To achieve these goals, the technical solution used in the present invention is:
A kind of autolyzed hemostasis composite, the mass fraction of component and each component is as follows: YUNNAN BAIYAO 5 ~ 15 parts, chitosan
10 ~ 30 parts, 2 ~ 5 parts of Alumen, cod-liver oil 4 ~ 10 parts, 2 ~ 8 parts of aminoacid, acetic acid 5 ~ 10 parts, chitosan 1 ~ 3 part, sorbic acid 6
~ 12 parts, 4 ~ 12 parts of gelatin, collagen protein 3 ~ 6 parts, sodium alginate 4 ~ 10 parts, sago starch 6 ~ 10 parts.
Described aminoacid is Pidolidone.
The deacetylation of described chitosan is 60%～70%.
Described one autolyzed hemostasis composite, the mass fraction of component and each component is as follows: YUNNAN BAIYAO 8 ~ 12
Part, chitosan 15 ~ 25 parts, 3 ~ 4 parts of Alumen, cod-liver oil 6 ~ 8 parts, 4 ~ 6 parts of aminoacid, acetic acid 6 ~ 8 parts, chitosan 1 ~ 3 part,
Sorbic acid 8 ~ 10 parts, 6 ~ 10 parts of gelatin, collagen protein 4 ~ 5 parts, sodium alginate 6 ~ 8 parts, sago starch 7 ~ 9 parts.
Described one autolyzed hemostasis composite, the mass fraction of component and each component is as follows: YUNNAN BAIYAO 10
Part, chitosan 20 parts, 3.5 parts of Alumen, cod-liver oil 7 parts, 5 parts of aminoacid, acetic acid 7 parts, chitosan 2 parts, sorbic acid 9 parts,
8 parts of gelatin, collagen protein 4.5 parts, sodium alginate 7 parts, sago starch 8 parts.
Chitosan, sodium alginate are dissolved in acetic acid, form polymeric dispersions system；It is subsequently adding remaining components, stirring,
It is dried to obtain autolyzed hemostasis composite.
Described baking temperature is 60 ~ 80 DEG C.
Beneficial effect:
The autolyzed hemostasis composite that the present invention provides can carry the strongest moistening recovery environment for wound；Biocompatibility
Good, it is possible to gradually to be absorbed by body, after contact lysis enzyme etc., it is possible to be gradually degraded into monosaccharide and be absorbed by the body；It is being used for
Time in body, need not take out, can reduce the pain of patient, reduce the secondary injury to wound, hemostasis is fast, easily absorbs, and uses
Convenient.
Detailed description of the invention
The deacetylation of the chitosan used in following example is 60%～70%, and relative molecular weight is 105～106.Real
Execute example 1
A kind of autolyzed hemostasis composite, the mass fraction of component and each component is as follows: YUNNAN BAIYAO 5 parts, chitosan 10
Part, 2 parts of Alumen, cod-liver oil 4 parts, 2 parts of aminoacid, acetic acid 5 parts, chitosan 1 part, sorbic acid 6 parts, 4 parts of gelatin, collagen
3 parts of albumen, sodium alginate 4 parts, sago starch 6 parts.
Chitosan, sodium alginate are dissolved in acetic acid, form polymeric dispersions system；It is subsequently adding remaining components, stirring,
70 DEG C are dried to obtain autolyzed hemostasis composite.
Embodiment 2
A kind of autolyzed hemostasis composite, the mass fraction of component and each component is as follows: YUNNAN BAIYAO 15 parts, chitosan 30
Part, 5 parts of Alumen, cod-liver oil 10 parts, 8 parts of aminoacid, acetic acid 10 parts, chitosan 3 parts, sorbic acid 12 parts, 12 parts of gelatin,
Collagen protein 6 parts, sodium alginate 10 parts, sago starch 10 parts.
Chitosan, sodium alginate are dissolved in acetic acid, form polymeric dispersions system；It is subsequently adding remaining components, stirring,
70 DEG C are dried to obtain autolyzed hemostasis composite.
Embodiment 3
A kind of autolyzed hemostasis composite, the mass fraction of component and each component is as follows: YUNNAN BAIYAO 8 parts, chitosan 15
Part, 3 parts of Alumen, cod-liver oil 6 parts, 4 parts of aminoacid, acetic acid 6 parts, chitosan 1 part, sorbic acid 8 parts, 6 parts of gelatin, collagen
4 parts of albumen, sodium alginate 6 parts, sago starch 7 parts.
Chitosan, sodium alginate are dissolved in acetic acid, form polymeric dispersions system；It is subsequently adding remaining components, stirring,
70 DEG C are dried to obtain autolyzed hemostasis composite.
Embodiment 4
A kind of autolyzed hemostasis composite, the mass fraction of component and each component is as follows: YUNNAN BAIYAO 12 parts, chitosan 25
Part, 4 parts of Alumen, cod-liver oil 8 parts, 6 parts of aminoacid, acetic acid 8 parts, chitosan 3 parts, sorbic acid 10 parts, 10 parts of gelatin, glue
5 parts of former albumen, sodium alginate 8 parts, sago starch 9 parts.
Chitosan, sodium alginate are dissolved in acetic acid, form polymeric dispersions system；It is subsequently adding remaining components, stirring,
70 DEG C are dried to obtain autolyzed hemostasis composite.
Embodiment 5
A kind of autolyzed hemostasis composite, the mass fraction of component and each component is as follows: YUNNAN BAIYAO 10 parts, chitosan 20
Part, 3.5 parts of Alumen, cod-liver oil 7 parts, 5 parts of aminoacid, acetic acid 7 parts, chitosan 2 parts, sorbic acid 9 parts, 8 parts of gelatin, glue
4.5 parts of former albumen, sodium alginate 7 parts, sago starch 8 parts.
Chitosan, sodium alginate are dissolved in acetic acid, form polymeric dispersions system；It is subsequently adding remaining components, stirring,
70 DEG C are dried to obtain autolyzed hemostasis composite.
Comparative example 1
A kind of autolyzed hemostasis composite, the mass fraction of component and each component is as follows: chitosan 20 parts, 3.5 parts of Alumen,
Cod-liver oil 7 parts, 5 parts of aminoacid, acetic acid 7 parts, chitosan 2 parts, sorbic acid 9 parts, 8 parts of gelatin, collagen protein 4.5 parts, sea
Sodium alginate 7 parts.(the most relatively, not containing YUNNAN BAIYAO and sago starch)
Chitosan, sodium alginate are dissolved in acetic acid, form polymeric dispersions system；It is subsequently adding remaining components, stirring, 70 DEG C
It is dried to obtain autolyzed hemostasis composite.
Comparative example 2
A kind of autolyzed hemostasis composite, the mass fraction of component and each component is as follows: YUNNAN BAIYAO 10 parts, chitosan 20
Part, 3.5 parts of Alumen, cod-liver oil 7 parts, 5 parts of aminoacid, acetic acid 7 parts, sorbic acid 9 parts, 8 parts of gelatin, sago starch 8 parts.
(the most relatively, not comprising collagen protein, sodium alginate, chitosan)
Chitosan is dissolved in acetic acid, forms polymeric dispersions system；Be subsequently adding remaining components, stirring, 70 DEG C be dried derive from
Dissolubility hemostasis composite.
The autolyzed hemostasis composite that embodiment 1 ~ 5 and comparative example 1 ~ 2 are prepared carry out compatibility experiments and
Clotting assay, experimental technique is as follows:
Platelet adhesion test
PAdT is the important indicator judging biomaterial blood compatibility.This experiment takes glass ball to respectively
The platelet adhesion of group ratio film is investigated.Result is as shown in table 1.According to country's pertinent regulations to biomaterial, material
Can be contacted when the platelet consumption rate of material is less than 40% use with blood.Each group film that this experiment prepares is relative to blank group
Platelet consumption rate is significantly less than this standard, has preferable blood compatibility.
Table 1
| Embodiment | 1 | 2 | 3 | 4 | 5 | Contrast 1 | Contrast 2 |
| Platelet consumption rate/% | 17.5% | 16.3% | 11.0% | 9.4% | 5.1% | 31.8% | 29.5% |
Dynamic blood coagulation is tested
The feelings of dynamic blood coagulation experiment (i.e. the anticoagulation function of material) the mainly degree that the detection intrinsic coagulation factor is activated
Condition.Research shows, the numerical value of anticoagulation parameter BCI of material can the anticoagulant characteristic of direct reaction material.In the time determined
In, the numerical value of BCI is the biggest, and the anticoagulation function of material is the best.The dynamic blood coagulation experimental result of embodiment 1-5 is as shown in table 2,
As can be seen from the table along with the prolongation of time of contact, the BCI value of material presents the trend of reduction,
Table 2:
| Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | |
| 5min | 63.2 | 68.1 | 77.5 | 73.5 | 81.9 |
| 10min | 48.3 | 55.9 | 66.1 | 60.7 | 76.4 |
| 20min | 35.4 | 37.1 | 48.6 | 42.4 | 68.8 |
| 30min | 21.5 | 25.3 | 30.3 | 31.3 | 541 |
Hemolytic test
Hemolytic experiment is that the erythrocyte in detection biomaterial and blood interacts, with evaluate its on erythrocytic impact one
The vital index of item.The hemolytic of material is the highest, shows that it is the biggest to the destructiveness of hemocyte.Embodiment 1-5
Hemolytic test the results are shown in Table 3, its hemolysis rate is below 5%, meets the requirement of biomaterial hemolytic experiment, has preferable blood
Liquid phase capacitive.
Table 3:
| Embodiment | 1 | 2 | 3 | 4 | 5 | Contrast 1 | Contrast 2 |
| Haemolysis degree/% | 3.7% | 3.8% | 3.5% | 2.1% | 1.6% | 4.8% | 5.3% |
It can be seen that the present invention autolyzed hemostasis composite has the blood compatibility of excellence from table 1-3, hemostasis is fast.
Claims (7)
1. an autolyzed hemostasis composite, it is characterised in that the mass fraction of component and each component is as follows: YUNNAN BAIYAO 5 ~
15 parts, chitosan 10 ~ 30 parts, 2 ~ 5 parts of Alumen, cod-liver oil 4 ~ 10 parts, 2 ~ 8 parts of aminoacid, acetic acid 5 ~ 10 parts, chitosan 1 ~
3 parts, sorbic acid 6 ~ 12 parts, 4 ~ 12 parts of gelatin, collagen protein 3 ~ 6 parts, sodium alginate 4 ~ 10 parts, sago starch 6 ~ 10 parts.
One the most according to claim 1 autolyzed hemostasis composite, it is characterised in that: described aminoacid is L-paddy ammonia
Acid.
One the most according to claim 1 autolyzed hemostasis composite, it is characterised in that: described chitosan deacetylated
Degree is 60%～70%.
One the most according to claim 1 autolyzed hemostasis composite, it is characterised in that: component and the quality of each component
Number is as follows: YUNNAN BAIYAO 8 ~ 12 parts, chitosan 15 ~ 25 parts, 3 ~ 4 parts of Alumen, cod-liver oil 6 ~ 8 parts, 4 ~ 6 parts of aminoacid,
Acetic acid 6 ~ 8 parts, chitosan 1 ~ 3 part, sorbic acid 8 ~ 10 parts, 6 ~ 10 parts of gelatin, collagen protein 4 ~ 5 parts, sodium alginate 6 ~ 8
Part, sago starch 7 ~ 9 parts.
One the most according to claim 1 autolyzed hemostasis composite, it is characterised in that: component and the quality of each component
Number is as follows: YUNNAN BAIYAO 10 parts, chitosan 20 parts, 3.5 parts of Alumen, cod-liver oil 7 parts, 5 parts of aminoacid, acetic acid 7 parts, several
Tetrose 2 parts, sorbic acid 9 parts, 8 parts of gelatin, collagen protein 4.5 parts, sodium alginate 7 parts, sago starch 8 parts.
6. the preparation method of a kind of autolyzed hemostasis composite described in claim 1, it is characterised in that: by chitosan, sea
Sodium alginate is dissolved in acetic acid, forms polymeric dispersions system；It is subsequently adding remaining components, stirring, dry that autolyzed hemostasis is multiple
Condensation material.
The preparation method of a kind of autolyzed hemostasis composite the most according to claim 6, it is characterised in that: described dry
Temperature is 60 ~ 80 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610474468.3A CN105963757A (en) | 2016-06-27 | 2016-06-27 | Autolyzed hemostatic composite material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610474468.3A CN105963757A (en) | 2016-06-27 | 2016-06-27 | Autolyzed hemostatic composite material and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105963757A true CN105963757A (en) | 2016-09-28 |
Family
ID=57019139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610474468.3A Pending CN105963757A (en) | 2016-06-27 | 2016-06-27 | Autolyzed hemostatic composite material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105963757A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003062057A (en) * | 2001-08-29 | 2003-03-04 | Next:Kk | Minute particles of biopolymer for homeostasis and adhesion prevention |
| CN105617448A (en) * | 2016-02-29 | 2016-06-01 | 苏州市贝克生物科技有限公司 | Fibrous protein compound hemostatic material and preparation method thereof |
| CN105617451A (en) * | 2016-02-29 | 2016-06-01 | 苏州市贝克生物科技有限公司 | Chitosan-based hemostatic material and preparation method thereof |
-
2016
- 2016-06-27 CN CN201610474468.3A patent/CN105963757A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003062057A (en) * | 2001-08-29 | 2003-03-04 | Next:Kk | Minute particles of biopolymer for homeostasis and adhesion prevention |
| CN105617448A (en) * | 2016-02-29 | 2016-06-01 | 苏州市贝克生物科技有限公司 | Fibrous protein compound hemostatic material and preparation method thereof |
| CN105617451A (en) * | 2016-02-29 | 2016-06-01 | 苏州市贝克生物科技有限公司 | Chitosan-based hemostatic material and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 卢斌等: "壳聚糖/海藻酸钠—云南白药复合膜止血效果实验研究", 《健康研究》 * |
| 吴万军: "《愉快农村居家必备的1000个生活窍门》", 30 September 2011, 印刷工业出版社 * |
| 徐宜厚: "《徐宜厚皮肤病用药心得十讲》", 31 January 2013, 中国医药科技出版社 * |
| 顾其胜，侯春林主编: "《医用几丁糖与临床医学》", 28 February 1997, 上海市其胜生物制剂有限公司、第二军医大学附属长征医院 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jin et al. | Microspheres of carboxymethyl chitosan, sodium alginate, and collagen as a hemostatic agent in vivo | |
| Wang et al. | Preparation and evaluation of chitosan/alginate porous microspheres/Bletilla striata polysaccharide composite hemostatic sponges | |
| CN106492260B (en) | Alginate-based hydrogel dressing and preparation method thereof | |
| CN103463669A (en) | Liquid wound dressing and preparation method thereof | |
| US9561300B2 (en) | Hemostatic compositions and dressings for bleeding | |
| WO2019126368A1 (en) | Dressing including dehydrated placental tissue for wound healing | |
| Lima et al. | Skin wounds, the healing process, and hydrogel-based wound dressings: A short review | |
| CN105770976B (en) | Dodecyl chitosan is preparing the application in bleeding-stopping dressing | |
| Shyna et al. | A nonadherent chitosan-polyvinyl alcohol absorbent wound dressing prepared via controlled freeze-dry technology | |
| Song et al. | Effects of degree of deacetylation on hemostatic performance of partially deacetylated chitin sponges | |
| CN105963760A (en) | Absorbable medical anti-microbial dressing and preparation method thereof | |
| CN107412843B (en) | Starch-based microporous hemostatic material with antibacterial property and preparation method and application thereof | |
| WO2022121255A1 (en) | Chitosan/mxene antibacterial composite sponge for hemostasis, preparation method therefor and application thereof | |
| CN103191462A (en) | Medical bleeding-stopping and disinfecting biological dressing | |
| CN106139239A (en) | Full-service fluid dressing and preparation method thereof | |
| CN101606949A (en) | A kind of is the quick hemostasis agent and the preparation technology thereof of primary raw material with high specific surface micro-pore starch | |
| CN106902383B (en) | Modified glucan modified nanogel hemostatic material and preparation and application thereof | |
| CN105477679B (en) | Based on the crosslinked chitosan quick-acting haemostatic powder cotton of polysaccharide | |
| CN113144280B (en) | Intelligent antibacterial hydrogel and application thereof | |
| CN107496973B (en) | Chitosan sponge pad band-aid capable of rapidly stopping bleeding and preparation method thereof | |
| Ma et al. | A bacteriostatic hemostatic dressing prepared from l-glutamine-modified chitosan, tannic acid-modified gelatin and oxidized dextran | |
| CN105963757A (en) | Autolyzed hemostatic composite material and preparation method thereof | |
| CN111012945B (en) | Waterproof traditional Chinese medicine liquid band-aid and preparation method thereof | |
| WO2013056116A1 (en) | Hemostatic dressing for arterial bleeding | |
| CN109731128B (en) | Absorbable and degradable biocompatible hemostatic material and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160928 |